Bioventus Reports Q1 Earnings and Raises Full-Year Guidance
Bioventus reported Q1 revenue of $132 million, a 7% year-over-year increase. The company raised its full-year adjusted EPS guidance to between $0.75–$0.79 and cash from operations to $84–$89 million while reaffirming annual revenue expectations of $600–$610 million.
Topics: capital_allocation financial_performance guidance_revision